All-In PodcastTrump's market impact: Bitcoin, M&A, IPOs + transition picks; Polymarket CEO raided by FBI
At a glance
WHAT IT’S REALLY ABOUT
Trump’s Win Supercharges Crypto, Shakes Markets, Media, And Bureaucracy
- The All-In besties unpack the market and political aftershocks of Trump’s election victory, focusing on the surge in Bitcoin and fintech, the prospects for IPOs and M&A, and a sharp turn in regulatory expectations. They argue that clearer crypto rules and a friendlier posture toward risk assets are driving a broad risk-on environment, even as high Treasury yields signal deep fiscal issues ahead.
- The conversation broadens into how Trump’s incoming cabinet could function as a deliberate ‘extinction event’ for parts of the federal bureaucracy, with high-beta picks like RFK Jr., Matt Gaetz, and Tulsi Gabbard framed as potentially transformative but risky. They also debate whether pharma advertising should be allowed on TV, given its role in media capture and healthcare inflation, and analyze the FBI raid on Polymarket’s CEO as either routine enforcement or possible political retribution.
- Throughout, they distinguish between disciplining ‘big tech’ monopolies versus enabling a healthier mid-cap M&A and IPO environment, and stress that doing nothing about federal bloat and lawfare is no longer a viable option.
IDEAS WORTH REMEMBERING
5 ideasTrump’s win has triggered a broad risk-on shift, especially for crypto and fintech.
Bitcoin hit an all-time high near $92K and crypto-exposed equities like Affirm, Robinhood, PayPal, and Coinbase are up 50–100% since late summer. Friedberg attributes this to expectations of lower taxes, deregulatory policy, and friendlier crypto rules, which increase risk appetite and capital flows into higher-yield, riskier assets. At the same time, the 10-year Treasury sitting around 4.5% with very tight credit spreads shows markets are both risk-seeking and beginning to reassess Treasuries as truly ‘risk-free’ given persistent deficits and inflation.
Despite optimism, the besties expect 2025 IPO and M&A activity to be more muted than VCs hope.
Chamath and Sacks argue that with risk-free Treasuries yielding ~4.5% (effectively 20x cash flow with no credit risk) and the S&P trading at rich multiples, it’s hard to justify paying aggressive IPO valuations for unprofitable SaaS and internet names. On M&A, Chamath is skeptical that ‘waiting out Lina Khan’ alone will suddenly unleash mega-deals; truly accretive, industrial-logic deals would already be happening if the economics justified them at current rates.
Clearer crypto regulation under Republicans (e.g., FIT21) could structurally re-rate the industry.
Sacks highlights the FIT21 bill, which would classify tokens on ‘functional and decentralized’ blockchains as commodities under the CFTC and more centralized ones as securities under the SEC. With Republicans now controlling the Senate and Gensler likely on his way out, the industry is close to the ‘rules of the road’ it’s wanted, ending the era of regulation-by-enforcement and ambiguous Wells notices. This regulatory clarity is a key driver behind the current crypto rally.
A healthier competitive landscape may require targeting big-tech dominance while freeing sub–$1T companies to consolidate.
Sacks praises Lina Khan’s willingness to pressure monopolies like Amazon, Apple, and Google, even as he faults her for over-broad enforcement that chilled small-tech M&A. J-Cal proposes a simple rule: restrict M&A for trillion-dollar-plus ‘Mag 7’ platforms but allow aggressive dealmaking among mid-cap tech and internet companies. In his view, letting Uber, DoorDash, Airbnb, Waymo-like spinouts, etc., merge and scale could create a ‘Mag 70’ and real competition, rather than further entrenching today’s top seven.
Pharma advertising on TV likely distorts news coverage and reinforces a captured healthcare system.
Sacks argues that most pharma TV spend is not about persuading consumers—who can’t buy drugs without prescriptions—but about purchasing favorable or selectively silent coverage from networks dependent on pharma ad revenue. Friedberg adds that healthcare and drug prices have been inflated by government programs and regulatory capture, making pharma exceptionally profitable and able to fund this influence loop. While he’s wary of government banning ads outright on free-speech grounds and notes some genuine public-health benefits of awareness campaigns, both agree the current arrangement is a ‘self-licking ice cream cone’ that keeps prices and capture high.
WORDS WORTH SAVING
5 quotesThere will be a point where Bitcoin is an independent asset and a non-speculative store of value… but that day is not now.
— Chamath Palihapitiya
You’re basically paying 20 times cash flow to own a risk-free bond, or 30 times to own the S&P 500. So what is this IPO going to give you?
— David Sacks
I would argue that Trump’s mandate was to be kind of the extinction event… this is going to be the most disruptive force that federal agencies have ever seen.
— David Friedberg
Why is so much money going from pharma to these news outlets? The real reason is it’s influence buying. It’s influence peddling.
— David Sacks
We all agree the United States is currently on an unsustainable fiscal path… What’s the downside of shaking it up?
— David Sacks
High quality AI-generated summary created from speaker-labeled transcript.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome